Experiences with
Anti TNF3,505 public posts
2025 Spring -Information only - NHS England notification of contingent liability - COVID-19 spring 2025 vaccination programme
Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide
Want to take advantage of all our features? Just log in!
or
Webinar: Could plants be used to treat macular disease?
Current treatments for wet age-related macular degeneration (AMD) have been life changing for many, helping to maintain vision. However, not all patients respond well to anti-VEGF injections, highlighting the need for alternative treatments. Professor Dulcie Mulholland and PhD student Elisha Griffin